Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase EARLY_PHASE1 1

Status

Withdrawn 1Terminated 1Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1NETWORK 1

Study Type

Interventional 4Observational 2

Sponsor

Cancer Type

Gastrointestinal 24Breast 23Other 9Lymphoid 6Thoracic 5Genitourinary 5Other hematologic neoplasm 4Gynecologic 4Endocrine 4CNS 4Plasma cell 2Dermatologic 2Sarcoma 1Myeloid 1

Conditions

Brain Neoplasms 1899Glioblastoma 1791Glioma 1126Central Nervous System Neoplasms 599Astrocytoma 593Neuroblastoma 552Gliosarcoma 465Oligodendroglioma 363Neoplasms 312Breast Neoplasms 273Medulloblastoma 272Carcinoma, Non-Small-Cell Lung 225Recurrence 198Sarcoma 183Neoplasm Metastasis 183Melanoma 181Meningioma 177Ependymoma 174Lung Neoplasms 156Lymphoma 133Osteosarcoma 126Meningeal Carcinomatosis 126Neurofibromatosis 1 114Wilms Tumor 111Ovarian Neoplasms 110Diffuse Intrinsic Pontine Glioma 105Precursor Cell Lymphoblastic Leukemia-Lymphoma 103Rhabdomyosarcoma 100Lymphoma, Non-Hodgkin 96Burkitt Lymphoma 89

Interventions

XENP 1595 2montelukast 1Tablets 1Platelet Count 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Inflammation × CNS × Clear all
NCT05522387 2026-02-27

An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease

Inmune Bio, Inc.

Phase 2 Terminated
11 enrolled
CNS

Alzheimer Disease, Mental Disorders, Brain Diseases, Central Nervous System Diseases, Dementia, Inflammation, Nervous System Diseases, Neurodegenerative Diseases, Neurocognitive Disorders, Tauopathies

NCT05049148 2026-01-05

Platon

Fondation Ophtalmologique Adolphe de Rothschild

Phase NA Recruiting
50 enrolled
CNS

Brain Neoplasms, Glioma, Inflammation

NCT06887673 2025-03-20

Lipid Mediators & Cancer: Montelukast, SPM, and Almonds

University of South Florida

Phase EARLY_PHASE1 Not yet recruiting
56 enrolled
CNSGastrointestinalGynecologicSarcoma

Brain Neoplasms, Inflammation, Ovarian Neoplasms, Sarcoma, Colorectal Neoplasms, Endometrial Neoplasms

NCT05321498 2023-09-28

Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation

Inmune Bio, Inc.

Phase 2 Withdrawn
CNS

Alzheimer Disease, Mental Disorders, Brain Diseases, Central Nervous System Diseases, Dementia, Inflammation, Nervous System Diseases, Neurodegenerative Diseases, Tauopathies, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡